Kyverna Therapeutics, Inc. (KYTX) is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company is advancing product candidates through preclinical studies and clinical trials, leveraging CAR-T and other cell therapy platforms. Kyverna aims to treat patients with serious autoimmune conditions, with plans for regulatory filings and potential commercialization of its pipeline candidates.
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001193125-26-126242 | EDGAR | 130K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-046074 | EDGAR | 128K words |
| 2024-03-26 | 2023-12-31 | 0000950170-24-036481 | EDGAR | 130K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001193125-26-344607 | EDGAR | 81K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-277584 | EDGAR | 80K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107321 | EDGAR | 78K words |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070325 | EDGAR | 74K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126366 | EDGAR | 77K words |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095462 | EDGAR | 75K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059628 | EDGAR | 74K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-24 | 0001193125-26-400062 | EDGAR | 2K words |
| 2026-08-11 | 0001193125-26-344572 | EDGAR | 2K words |
| 2026-07-27 | 0001193125-26-316916 | EDGAR | 1K words |
| 2026-03-26 | 0001193125-26-126216 | EDGAR | 3K words |
| 2026-02-24 | 0001193125-26-065320 | EDGAR | 1K words |
| 2026-02-03 | 0001193125-26-034464 | EDGAR | 1K words |
| 2026-01-12 | 0001193125-26-009810 | EDGAR | 1K words |
| 2025-12-18 | 0001213900-25-123033 | EDGAR | 1K words |
| 2025-12-15 | 0001193125-25-318469 | EDGAR | 3K words |
| 2025-12-15 | 0001193125-25-318377 | EDGAR | 2K words |
53 total filings indexed. 33 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001994702 |
| Ticker | KYTX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.kyvernatx.com |
| Listed | 2024-02-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KYTX (~200 tokens, structured JSON with cryptographic provenance)